Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Doriano Fabbro

Showing results (91-100 of 121) with videos related to

Pageof 13
Sort By:
Scientific Reports|October 24, 2018
Author Correction: Acylated-acyl carrier protein stabilizes the Pseudomonas aeruginosa WaaP lipopolysaccharide heptose kinaseNaomi N K Kreamer, Rajiv Chopra, Ruth E Caughlan, et al.
Molecular Cancer Therapeutics|July 9, 2008
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activitySauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen, et al.
Nucleic Acids Research|October 15, 2015
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligandsChristopher Southan, Joanna L Sharman, Helen E Benson, et al.
Oncogene|August 11, 2005
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignanciesJing Chen, Benjamin H Lee, Ifor R Williams, et al.
Biochimica Et Biophysica Acta|February 16, 2010
Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding siteDoriano Fabbro, Paul W Manley, Wolfgang Jahnke, et al.
Journal of Medicinal Chemistry|August 23, 2017
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in OncologyFlorent Beaufils, Natasa Cmiljanovic, Vladimir Cmiljanovic, et al.
Cancer Cell|March 31, 2004
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinaseCarlos García-Echeverría, Mark A Pearson, Andreas Marti, et al.
Pharmacological Reviews|July 17, 2014
International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligandsArthur Christopoulos, Jean-Pierre Changeux, William A Catterall, et al.
British Journal of Pharmacology|October 22, 2017
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: OverviewStephen Ph Alexander, Eamonn Kelly, Neil V Marrion, et al.
Nucleic Acids Research|November 18, 2017
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGYSimon D Harding, Joanna L Sharman, Elena Faccenda, et al.
Pageof 13

Showing results (91-100 of 121) with videos related to

Sort By:
Pageof 13
Scientific Reports|October 24, 2018
Author Correction: Acylated-acyl carrier protein stabilizes the Pseudomonas aeruginosa WaaP lipopolysaccharide heptose kinaseNaomi N K Kreamer, Rajiv Chopra, Ruth E Caughlan, et al.
Molecular Cancer Therapeutics|July 9, 2008
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activitySauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen, et al.
Nucleic Acids Research|October 15, 2015
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligandsChristopher Southan, Joanna L Sharman, Helen E Benson, et al.
Oncogene|August 11, 2005
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignanciesJing Chen, Benjamin H Lee, Ifor R Williams, et al.
Biochimica Et Biophysica Acta|February 16, 2010
Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding siteDoriano Fabbro, Paul W Manley, Wolfgang Jahnke, et al.
Journal of Medicinal Chemistry|August 23, 2017
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in OncologyFlorent Beaufils, Natasa Cmiljanovic, Vladimir Cmiljanovic, et al.
Cancer Cell|March 31, 2004
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinaseCarlos García-Echeverría, Mark A Pearson, Andreas Marti, et al.
Pharmacological Reviews|July 17, 2014
International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligandsArthur Christopoulos, Jean-Pierre Changeux, William A Catterall, et al.
British Journal of Pharmacology|October 22, 2017
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: OverviewStephen Ph Alexander, Eamonn Kelly, Neil V Marrion, et al.
Nucleic Acids Research|November 18, 2017
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGYSimon D Harding, Joanna L Sharman, Elena Faccenda, et al.
Pageof 13